Roche’s Genentech licenses Hanmi obesity candidate HM17321 in deal worth up to $2.3 billion

The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline. Hanmi Pharm has granted Roche subsidiary Genentech exclusive rights to develop, manufacture and commercialise HM17321 outside South Korea for $190 million upfront, with the total deal value potentially reaching approximately $2.3 billion through development, regulatory and commercial milestones. 

The Phase I UCN2 analogue provides Roche with a non-incretin obesity programme designed to promote weight loss while preserving lean body mass, potentially complementing incretin-based approaches already being developed across the obesity market.

Field	Content
Alert Type	Deal
Companies	Hanmi Pharm; Genentech, a member of the Roche Group
Deal Type	Exclusive licensing agreement
Asset or Company	HM17321
Therapy Area(s)	Obesity; Metabolic disease; Type 2 diabetes; Cardiovascular disease
Technology or Modality	Long-acting UCN2 (urocortin-2) analogue; non-incretin peptide therapeutic
Deal Value	$190 million upfront. Hanmi is eligible for additional development, regulatory and commercial milestone payments that could bring the total deal value to approximately $2.3 billion, plus separate tiered royalties on future net sales. The amount above the upfront payment is contingent and should not be treated as guaranteed consideration. (Hanmi Pharmaceutical)
Development Stage	Phase I (Hanmipharm)
Geography	Worldwide excluding South Korea
What Happened	On 24 August 2026, Hanmi Pharm entered an exclusive licensing agreement with Genentech covering HM17321, its investigational UCN2 analogue for obesity and associated metabolic conditions. Genentech receives exclusive development, manufacturing and commercialisation rights worldwide excluding South Korea. Hanmi will receive $190 million upfront, with development, regulatory and commercial milestones potentially taking the transaction to approximately $2.3 billion, plus tiered royalties on future sales. HM17321 is currently in Phase I development; Hanmi will complete the ongoing Phase I study before Genentech assumes development from Phase II. (Hanmi Pharmaceutical)
Why It Matters	HM17321 gives Roche access to an obesity mechanism distinct from the incretin pathways underlying established GLP-1-based therapies. The candidate is designed to selectively reduce fat mass while preserving or improving muscle mass and function, potentially addressing concerns around loss of lean body mass during weight reduction. These potential advantages are not yet clinically established, however, and HM17321 remains in early-stage development. (Hanmi Pharmaceutical)
Supporting Context	HM17321 is a long-acting, CRF2 receptor-selective UCN2 analogue developed by Hanmi. The company has reported preclinical evidence of weight reduction and body-composition effects both as monotherapy and in combination with GLP-1-based treatment, but these findings require confirmation in clinical development. (PR Newswire)
Strategic Rationale	Genentech gains worldwide ex-South Korea rights to a differentiated obesity candidate that can broaden Roche’s cardiometabolic pipeline beyond conventional incretin mechanisms. Hanmi receives substantial upfront consideration while retaining South Korean rights and an economic interest in the programme through milestones and tiered royalties. (Hanmi Pharmaceutical)
Potential Impact	If HM17321 demonstrates clinically meaningful weight reduction while preserving lean mass, the programme could provide Roche with a differentiated standalone or combination approach within obesity and related metabolic diseases. That potential remains dependent on successful clinical development and regulatory approval.
Key Takeaway	Roche is committing $190 million upfront for access to a non-incretin obesity programme designed around weight loss and lean-mass preservation, with milestones potentially taking Hanmi’s deal to approximately $2.3 billion.
What to Watch	Completion of HM17321’s Phase I programme, Genentech’s transition into Phase II development and the first clinical evidence showing whether the body-composition effects reported preclinically translate into people with obesity. (M2 Pharma)
Primary Source	Hanmi Pharm official licensing announcement (Hanmi Pharmaceutical)
Relevant Date	24 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com